This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

Who's Doing What in Pharmaceutical R&D? Model

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
Fabio Pammolli (IMT, Lucca Institute for Advanced Studies)
Massimo Riccaboni (University of Florence)
Laura Magazzini (University of Verona, Department of Economics)

Additional information is available for the following registered author(s):

Abstract

The research effort undertaken by firms is driven by a multiple set of factors and incentives. The debate in the theoretical literature has focused the attention on “technology push” versus “demand pull” theories, the former considering the exogenous effect of science on technological change, while the latter regarding market growth and size as unique determinants of the decision to invest in R&D. Both theories tell only part of the story. The decision to invest in R&D, and therefore the rate and direction of technological progress, is the result of the interplay between the advances spanning from basic science, institutional variables, and economic factors, namely market growth and size. In this paper we investigate the pharmaceutical industry, where R&D has clear implications for the welfare and health of the population, and both patient needs and technological progress play a fundamental role in the innovation process. We ask what drives pharmaceutical R&D investments in specific therapeutic submarkets. To address this question it is essential to map the research effort of firms (both established pharmaceutical firms and new biotechnology firms) and public research organizations in terms of the epidemiological characteristics and the severity of the disease targeted by their R&D projects. Moreover, we take into consideration the nationality of the main corporations performing R&D in the pharmaceutical industry, with clear implications for the recent debate viewing Europe as a “free rider” on US innovations.

Download Info
To download:

If you experience problems downloading a file, check if you have the proper application to view it first. Information about this may be contained in the File-Format links below. In case of further problems read the IDEAS help file. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://www.imtlucca.it/whos_at_imt/faculty/_publications/Whos_Doing_What_in_Pharmaceutical_R&D.pdf
File Format: application/pdf
File Function:
Download Restriction: no

Publisher Info
Paper provided by Economics, Markets, Institutions - IMT Institutions, Markets, Technologies - Institute for Advanced Studies Lucca in its series Working Papers with number 2.

Download reference. The following formats are available: HTML, plain text, BibTeX, RIS (EndNote), ReDIF
Length: 22 pages
Date of creation: 2007
Date of revision:
Handle: RePEc:ial:wpaper:wdwprd

Contact details of provider:
Postal: Piazza S. Ponziano, 6, 55100 Lucca
Phone: +39 0583 4326561
Fax: +39 0583 4326565
Web page: http://www.imtlucca.it/
More information through EDIRC

For technical questions regarding this item, or to correct its listing, contact: ().

Related research
Keywords: pharmaceutical R&D technology push demand pull market growth technological progress economic factors pharmaceutical investments

Find related papers by JEL classification:
O31 - Economic Development, Technological Change, and Growth - - Technological Change - - - Innovation and Invention: Processes and Incentives
L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

  1. Patricia M. Danzon & Sean Nicholson & Nuno Sousa Pereira, 2003. "Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances," NBER Working Papers 9615, National Bureau of Economic Research, Inc. [Downloadable!] (restricted)
    Other versions:
  2. Jason Owen-Smith & Massimo Riccaboni & Fabio Pammolli & Walter W. Powell, 2001. "A Comparison of U.S. And European University-Industry Relations in the Life Sciences," LEM Papers Series 2001/03, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
  3. Amy Finkelstein, 2003. "Health Policy and Technological Change: Evidence from the Vaccine Industry," NBER Working Papers 9460, National Bureau of Economic Research, Inc. [Downloadable!] (restricted)
  4. Sanghoon Ahn, 2002. "Competition, Innovation and Productivity Growth: A Review of Theory and Evidence," OECD Economics Department Working Papers 317, OECD Economics Department. [Downloadable!]
  5. Lerner, Josh, 1995. "Patenting in the Shadow of Competitors," Journal of Law & Economics, University of Chicago Press, vol. 38(2), pages 463-95, October.
  6. Lanjouw, Jean O. & Cockburn, Iain M., 2001. "New Pills for Poor People? Empirical Evidence after GATT," World Development, Elsevier, vol. 29(2), pages 265-289, February. [Downloadable!] (restricted)
  7. Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc. [Downloadable!] (restricted)
    Other versions:
  8. Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc. [Downloadable!] (restricted)
  9. Wright, Brian Davern, 1983. "The Economics of Invention Incentives: Patents, Prizes, and Research Contracts," American Economic Review, American Economic Association, vol. 73(4), pages 691-707, September. [Downloadable!] (restricted)
  10. Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall. [Downloadable!] (restricted)
  11. Alessandro Sembenelli & Davide Vannoni, 2000. "Why Do Established Firms Enter Some Industries and Exit Others? Empirical Evidence on Italian Business Groups," Review of Industrial Organization, Springer, vol. 17(4), pages 441-456, December. [Downloadable!] (restricted)
  12. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March. [Downloadable!] (restricted)
Full references

Statistics
Access and download statistics

Did you know? RePEc and its associated services are free for contributors and users, and do not accept any advertising.

This page was last updated on 2008-10-23.


This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.